Beatrice Dozin1, Grazia Carbotti2, Silvio Roncella3, Paola Ferro3, Paolo Dessanti3, Pier Aldo Canessa4, Silvano Ferrini2, Marina Fabbi5. 1. Clinical Epidemiology Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy. 2. Biotherapies Unit, IRCCS Ospedale Policlinico San Martino, Largo Benzi 10, 16132, Genoa, Italy. 3. Histopathology and Cytopathology Division, Azienda Sanitaria Locale N. 5 , La Spezia, Italy. 4. Pneumology Division, Azienda Sanitaria Locale N. 5 , La Spezia, Italy. 5. Biotherapies Unit, IRCCS Ospedale Policlinico San Martino, Largo Benzi 10, 16132, Genoa, Italy. marina.fabbi@hsanmartino.it.
Abstract
BACKGOUND: Literature reports suggest that the host immune system may control Malignant Pleural Mesothelioma (MPM) growth, although its activity is limited by regulatory mechanisms. In this retrospective study, we analyzed the levels of pro-inflammatory (IL-1, IL-6, TNF), immune-regulatory (IL-10) and Th1/CTL-related cytokines (IL-12p70, IFN-γ) in the pleural exudate and their relationship with overall survival (OS) in MPM. METHODS: Cytokines were quantified by multiplexed immunoassay. Concentrations were dichotomized with respect to the median value. Correlation between cytokine level and OS was assessed using univariate (Kaplan-Meier curves) and multivariate (Cox regression) analyses. RESULTS: Regarding outcome, tumor histology, therapies undergone and IFN-γ were independent prognostic factors of OS in a 72 MPM training cohort. Notably, high concentrations of IFN-γ halved death probability (HR of high vs low IFN-γ concentration = 0.491, 95%CI 0.3-0.8, p = 0.007). Also in patients with epithelioid histology and those receiving at least one line of therapy, high IFN-γ level was an independent factor predictive of OS (HR of high vs low IFN-γ concentration were 0.497, p = 0.007 and 0.324, p = 0.006, respectively). However, these data were not confirmed in a 77 MPM validation cohort, possibly due to the low IFN-γ levels encountered in this population, and the heterogeneous distribution of disease stages between the training and the validation cohorts. None of the other cytokines showed any effect on survival. CONCLUSIONS: High level of IFN-γ in pleural effusion may be associated with better survival in MPM patients and potentially serve as a prognostic biomarker. Larger prospective studies are needed to ascertain this hypothesis.
BACKGOUND: Literature reports suggest that the host immune system may control Malignant Pleural Mesothelioma (MPM) growth, although its activity is limited by regulatory mechanisms. In this retrospective study, we analyzed the levels of pro-inflammatory (IL-1, IL-6, TNF), immune-regulatory (IL-10) and Th1/CTL-related cytokines (IL-12p70, IFN-γ) in the pleural exudate and their relationship with overall survival (OS) in MPM. METHODS: Cytokines were quantified by multiplexed immunoassay. Concentrations were dichotomized with respect to the median value. Correlation between cytokine level and OS was assessed using univariate (Kaplan-Meier curves) and multivariate (Cox regression) analyses. RESULTS: Regarding outcome, tumor histology, therapies undergone and IFN-γ were independent prognostic factors of OS in a 72 MPM training cohort. Notably, high concentrations of IFN-γ halved death probability (HR of high vs low IFN-γ concentration = 0.491, 95%CI 0.3-0.8, p = 0.007). Also in patients with epithelioid histology and those receiving at least one line of therapy, high IFN-γ level was an independent factor predictive of OS (HR of high vs low IFN-γ concentration were 0.497, p = 0.007 and 0.324, p = 0.006, respectively). However, these data were not confirmed in a 77 MPM validation cohort, possibly due to the low IFN-γ levels encountered in this population, and the heterogeneous distribution of disease stages between the training and the validation cohorts. None of the other cytokines showed any effect on survival. CONCLUSIONS: High level of IFN-γ in pleural effusion may be associated with better survival in MPM patients and potentially serve as a prognostic biomarker. Larger prospective studies are needed to ascertain this hypothesis.
Authors: Michele Carbone; Prasad S Adusumilli; H Richard Alexander; Paul Baas; Fabrizio Bardelli; Angela Bononi; Raphael Bueno; Emanuela Felley-Bosco; Francoise Galateau-Salle; David Jablons; Aaron S Mansfield; Michael Minaai; Marc de Perrot; Patricia Pesavento; Valerie Rusch; David T Severson; Emanuela Taioli; Anne Tsao; Gavitt Woodard; Haining Yang; Marjorie G Zauderer; Harvey I Pass Journal: CA Cancer J Clin Date: 2019-07-08 Impact factor: 508.702
Authors: Joachim G J V Aerts; Pauline L de Goeje; Joost P J J Hegmans; Henk C Hoogsteden; Robin Cornelissen; Margaretha E H Kaijen-Lambers; Koen Bezemer; Cor H van der Leest; Niken M Mahaweni; André Kunert; Ferry A L M Eskens; Cynthia Waasdorp; Eric Braakman; Bronno van der Holt; Arnold G Vulto; Rudi W Hendriks Journal: Clin Cancer Res Date: 2017-12-12 Impact factor: 12.531
Authors: Joost P Hegmans; Joris D Veltman; Margaretha E Lambers; I Jolanda M de Vries; Carl G Figdor; Rudi W Hendriks; Henk C Hoogsteden; Bart N Lambrecht; Joachim G Aerts Journal: Am J Respir Crit Care Med Date: 2010-02-18 Impact factor: 21.405
Authors: Michele Maio; Arnaud Scherpereel; Luana Calabrò; Joachim Aerts; Susana Cedres Perez; Alessandra Bearz; Kristiaan Nackaerts; Dean A Fennell; Dariusz Kowalski; Anne S Tsao; Paul Taylor; Federica Grosso; Scott J Antonia; Anna K Nowak; Maria Taboada; Martina Puglisi; Paul K Stockman; Hedy L Kindler Journal: Lancet Oncol Date: 2017-07-17 Impact factor: 41.316
Authors: Robin Cornelissen; Joost P J J Hegmans; Alexander P W M Maat; Margaretha E H Kaijen-Lambers; Koen Bezemer; Rudi W Hendriks; Henk C Hoogsteden; Joachim G J V Aerts Journal: Am J Respir Crit Care Med Date: 2016-05-01 Impact factor: 21.405
Authors: Maria J Disselhorst; Josine Quispel-Janssen; Ferry Lalezari; Kim Monkhorst; Jeltje F de Vries; Vincent van der Noort; Emmy Harms; Sjaak Burgers; Paul Baas Journal: Lancet Respir Med Date: 2019-01-16 Impact factor: 30.700